Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Liver Cirrhosis

  Free Subscription


06.05.2024

1 Dig Dis Sci
2 Hepatology
2 J Gastroenterol Hepatol
1 J Hepatol
2 N Engl J Med
1 PLoS One
2 Transplant Proc


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Dig Dis Sci

  1. PEMMASANI G, Tremaine W, Karagozian R, John S, et al
    Impact of Cirrhosis Etiology on the Risk for Venous Thromboembolism.
    Dig Dis Sci. 2024 May 3. doi: 10.1007/s10620-024-08440.
    PubMed         Abstract available


    Hepatology

  2. KUMAR M, Venishetty S
    Reply: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - A randomized controlled trial.
    Hepatology. 2024 Apr 30. doi: 10.1097/HEP.0000000000000916.
    PubMed        

  3. CHOPRA SY, Rawat VL, Ingle MA, Lad SG, et al
    Letter to Editor: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
    Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000915.
    PubMed        


    J Gastroenterol Hepatol

  4. ENDO K, Kakisaka K, Abe T, Yusa K, et al
    Positive impact of obesity on the prognosis of liver cirrhosis.
    J Gastroenterol Hepatol. 2024 May 3. doi: 10.1111/jgh.16590.
    PubMed         Abstract available

  5. MAKRI ES, Evripidou K, Polyzos SA
    Circulating leptin in patients with nonalcoholic fatty liver disease-related liver fibrosis: a systematic review and a meta-analysis.
    J Gastroenterol Hepatol. 2024;39:806-817.
    PubMed         Abstract available


    J Hepatol

  6. OLLIVIER-HOURMAND I, Lebedel L, Bartroli Alabau B, Goria O, et al
    Recurrent splanchnic and extrasplanchnic thrombotic events in patients with non-cirrhotic portal vein thrombosis associated with local factors.
    J Hepatol. 2024 Apr 26:S0168-8278(24)00284-8. doi: 10.1016/j.jhep.2024.
    PubMed         Abstract available


    N Engl J Med

  7. HARRISON SA, Taub R
    A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply.
    N Engl J Med. 2024;390:1632-1633.
    PubMed        

  8. SABET A
    A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis.
    N Engl J Med. 2024;390:1632.
    PubMed        


    PLoS One

  9. BENGTSSON B, Maucourant C, Sandberg JK, Bjorkstrom NK, et al
    Evaluation of mucosal-associated invariant T-cells as a potential biomarker to predict infection risk in liver cirrhosis.
    PLoS One. 2024;19:e0294695.
    PubMed         Abstract available


    Transplant Proc

  10. KANG SW, Ban JY, Park MS
    Protective Role of Rapamycin in Fibrotic Liver Ischemia/Reperfusion Injury (C57bl/6 Mouse).
    Transplant Proc. 2024;56:672-677.
    PubMed         Abstract available

  11. KANG HG, Park H, Myong GE, Kim WJ, et al
    Beneficial Effect of Rapamycin on Liver Fibrosis in a Mouse Model (C57bl/6 Mouse).
    Transplant Proc. 2024;56:701-704.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.